Explore Ultragenyx's 2024 financial report highlighting $560M revenue growth, $569M net loss, and strategic recommendations for investors. A cautious outlook amid market pressures.
Explore Ultragenyx Pharmaceutical Inc.'s significant corporate event reported on February 13, 2025. This 8-K filing highlights important developments for investors in the biotech sector.
Explore Ultragenyx Pharmaceutical Inc.'s 8-K report filed on January 12, 2025, detailing significant corporate events impacting RARE stock and financial status.
Explore Ultragenyx Pharmaceutical's latest 8-K filing from December 19, 2024, highlighting significant updates relevant to investors. Ticker: RARE, NASDAQ.